‘Blow Your Mind’ Survival Improvement in Advanced, Mutated NSCLC

(MedPage Today) — BERLIN — Almost half of patients with advanced ALK-positive non-small cell lung cancer (NSCLC) have lived 7 years or longer following initial treatment with the ALK inhibitor alectinib (Alecensa), an updated analysis of a…